Innovation

Australia’s medical technology sector will take centre stage in May when AusBiotech brings its flagship AusMedtech conference to Perth for the first time.

Medical Developments International (ASX:MVP) has reported a steady first-half performance for the financial year 2026, with growth in its flagship pain relief product helping to underpin revenue and cash flow despite softer conditions in its respiratory business.

CSL has taken another step in its push to expand its portfolio of innovative therapies, announcing a new licensing agreement with Eli Lilly that could broaden the future reach of its monoclonal antibody candidate, clazakizumab.

Australian pharmaceutical manufacturer IDT says it is beginning to show tangible signs of recovery after a period of leadership change and financial pressure, reporting improved earnings and renewed operational momentum in the first half of the financial year 2026.

Nyrada (ASX:NYR) has confirmed growing clinical momentum, strengthening finances, and expanding scientific validation for its lead candidate, Xolatryp, as the company positions itself for its next phase of development.

Percheron Therapeutics (ASX:PER) is positioning itself as a small but strategically focused biotechnology company seeking to carve out a role in the rapidly expanding immuno-oncology market.

Telix Pharmaceuticals (ASX:TLX) has taken another step in expanding its neuro-oncology portfolio, announcing the submission of a European marketing authorisation application for its brain cancer imaging candidate TLX101-Px.

Australia’s life sciences sector is set for a stronger, more coordinated innovation pipeline following a new national partnership between industry body AusBiotech and biomedical venture creator Proto Axiom.

Botanix Pharmaceuticals (ASX:BOT) has taken a major step to strengthen its commercial momentum and long-term manufacturing strategy, securing commitments for approximately $45 million in fresh capital as it looks to expand production, stabilise supply and accelerate growth of its lead dermatology product, Sofdra.

A new prostate cancer imaging technology from Clarity Pharmaceuticals (ASX:CU6) is showing promise in improving the detection of recurrent disease, after results from a comparative clinical study indicated it may outperform the current standard of care.

Emyria’s (ASX:EMD) push to scale its insurer-backed mental health services across Australia has taken a significant step forward, with Medibank expanding its funding agreement to support patients at the company’s new Mornington Peninsula clinic in Victoria.

Chimeric Therapeutics has strengthened its leadership, appointing experienced biotechnology executive Dr Bradley Glover as Non-Executive Director and Chair, and naming a new Chief Financial Officer, as part of a broader governance refresh.